PURPOSE AND METHODS: High-level DNA amplifications are recurrently found in breast cancer, and some of them are associated with poor patient prognosis. To determine their frequency and co-occurrence in familial breast cancer, we have analyzed 80 tumors previously characterized for BRCA1 and BRCA2 germ-line mutations (26 BRCA1, 18 BRCA2, and 36 non-BRCA1/2) using high-resolution comparative genomic hybridization. RESULTS: Twenty-one regions were identified as recurrently amplified, such as 8q21-23 (26.25%), 17q22-25 (13.75%), 13q21-31 (12.50%), and 8q24 (11.25%), many of which were altered in each familial breast cancer group. These amplifications defined an amplifier phenotype that is correlated with a higher genomic instability. Based on these amplifications, two different genomic pathways have been established in association with 8q21-23 and/or 17q22-25 and with 13q21-31 amplification. These pathways are associated with specific genomic regions of amplification, carry specific immunohistochemical characteristics coincident with high and low aggressiveness, and have a trend to be associated with BRCA1 and BRCA2/X, respectively. CONCLUSION: In summary, our data suggest the existence of two different patterns of evolution, probably common to familial and sporadic breast tumors.
PURPOSE AND METHODS: High-level DNA amplifications are recurrently found in breast cancer, and some of them are associated with poor patient prognosis. To determine their frequency and co-occurrence in familial breast cancer, we have analyzed 80 tumors previously characterized for BRCA1 and BRCA2 germ-line mutations (26 BRCA1, 18 BRCA2, and 36 non-BRCA1/2) using high-resolution comparative genomic hybridization. RESULTS: Twenty-one regions were identified as recurrently amplified, such as 8q21-23 (26.25%), 17q22-25 (13.75%), 13q21-31 (12.50%), and 8q24 (11.25%), many of which were altered in each familial breast cancer group. These amplifications defined an amplifier phenotype that is correlated with a higher genomic instability. Based on these amplifications, two different genomic pathways have been established in association with 8q21-23 and/or 17q22-25 and with 13q21-31 amplification. These pathways are associated with specific genomic regions of amplification, carry specific immunohistochemical characteristics coincident with high and low aggressiveness, and have a trend to be associated with BRCA1 and BRCA2/X, respectively. CONCLUSION: In summary, our data suggest the existence of two different patterns of evolution, probably common to familial and sporadic breast tumors.
Authors: Lorenzo Melchor; Laura Paula Saucedo-Cuevas; Iván Muñoz-Repeto; Socorro María Rodríguez-Pinilla; Emiliano Honrado; Alfredo Campoverde; Jose Palacios; Katherine L Nathanson; María José García; Javier Benítez Journal: Breast Cancer Res Date: 2009-12-08 Impact factor: 6.466
Authors: Jennifer A Byrne; Sanaz Maleki; Jayne R Hardy; Brian S Gloss; Rajmohan Murali; James P Scurry; Susan Fanayan; Catherine Emmanuel; Neville F Hacker; Robert L Sutherland; Anna Defazio; Philippa M O'Brien Journal: BMC Cancer Date: 2010-09-17 Impact factor: 4.430
Authors: Louis-Romée Le Nail; Meadhbh Brennan; Philippe Rosset; Frédéric Deschaseaux; Philippe Piloquet; Olivier Pichon; Cédric Le Caignec; Vincent Crenn; Pierre Layrolle; Olivier Hérault; Gonzague De Pinieux; Valérie Trichet Journal: Int J Mol Sci Date: 2018-03-01 Impact factor: 5.923
Authors: P Lebok; V Kopperschmidt; M Kluth; C Hube-Magg; C Özden; Taskin B; K Hussein; A Mittenzwei; A Lebeau; I Witzel; L Wölber; S Mahner; F Jänicke; S Geist; P Paluchowski; C Wilke; U Heilenkötter; Ronald Simon; Guido Sauter; L Terracciano; R Krech; A von d Assen; V Müller; E Burandt Journal: BMC Cancer Date: 2015-12-16 Impact factor: 4.430
Authors: Charlotte L T Jørgensen; Bent Ejlertsen; Karsten D Bjerre; Eva Balslev; Dorte L Nielsen; Kirsten V Nielsen Journal: BMC Cancer Date: 2013-11-12 Impact factor: 4.430